Spero Therapeutics, Inc. SPRO
1.04 USD +0.02 (+1.96%)
Nov 6, 2026, 12:03 PM EST
1.01 Day range 1.05
0.961 52-week range 3.08
- YTD
- -55.36%
- 1 year
- -56.49%
News
globenewswire.com Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in…
globenewswire.com Spero Therapeutics to Present at Investor Conferences in November CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in…
benzinga.com This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday Analysts initiated bullish coverage on Rubrik, Kardigan, MSG Rangers and Ormat Technologies, with price targets of $155, $50, $257 and $123.
benzinga.com This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Analysts initiated coverage: Hold ALHC; Overweight/$6 SPRO; Buy/$3 LABT; Buy/$6 CLOV.
benzinga.com Cantor Fitzgerald Initiates Coverage On Spero Therapeutics with Overweight Rating, Announces Price Target of $6 Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Spero Therapeutics (NASDAQ:SPRO) with a Overweight rating and announces Price Target of $6.
benzinga.com Meta Platforms To $650? Here Are 10 Top Analyst Forecasts For Monday Analysts raised price targets for Meta, IREN, Coinbase, Roblox and others; IREN and Coinbase were upgraded, while other ratings held steady.- benzinga.com HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $6 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spero Therapeutics (NASDAQ:SPRO) with a Buy and raises the price target from $5 to $6.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals…- benzinga.com Spero Therapeutics Announces $105M In Non-Recourse Non-Dilutive Royalty Financing With KKR's Healthcare Royalty Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent BiologicsTransaction unlocks immediate value from future Utebzi (tebipenem pivoxil)…
- benzinga.com Spero Therapeutics Enters License Agreement With Innovent Biologics For Exclusive Rights To Develop, Research, Manufacture, And Commercialize SP001 Globally Ex-China Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355)Innovent will receive an…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating earnings and revenue estimates. Other gainers include LNKS, ADTX, and SPRO.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs FDA approves GSK and SPRO's Utebzi, the first oral carbapenem for cUTIs. Launch planned for late 2026. See market reaction.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com GSK, Spero Therapeutics Announce FDA Approves Utebzi To Treat Complicated Urinary Tract Infections https://www.gsk.com/en-gb/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adults-with-complicated-urinary-tract-infections-cutis/
benzinga.com Spero Therapeutics Q1 EPS $(0.13) Beats $(0.18) Estimate, Sales $258.000K Down From $5.874M YoY Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 48 percent increase over losses of…
benzinga.com Earnings Scheduled For May 13, 2026 - benzinga.com Earnings Scheduled For March 26, 2026
- benzinga.com Earnings Scheduled For November 13, 2025
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Earnings Scheduled For August 12, 2025
benzinga.com Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Crude Oil Gains 2%; Macy's Lowers Earnings Forecast 
benzinga.com US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Earnings Scheduled For May 13, 2025
- benzinga.com Earnings Scheduled For March 27, 2025
benzinga.com Earnings Scheduled For November 14, 2024 - benzinga.com Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.
- benzinga.com Earnings Scheduled For March 13, 2024 Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
- benzinga.com 5 Value Stocks In The Healthcare Sector
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Earnings Scheduled For November 13, 2023 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 311 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 647 companies set new 52-week lows.
- benzinga.com Earnings Scheduled For August 10, 2023 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
- benzinga.com Earnings Scheduled For May 11, 2023 Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its…
- benzinga.com Earnings Scheduled For March 30, 2023 Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million.
benzinga.com Earnings Scheduled For November 14, 2022 Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.- benzinga.com Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday Gainers
- benzinga.com Why Korn Ferry Is Trading Lower By Over 8%, Here Are 40 Stocks Moving In Wednesday's Mid-Day Session Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 64% to $0.1199. Allena Pharmaceuticals shares dipped over 30% on Tuesday after the company announced it has filed for bankruptcy.
- benzinga.com Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
- benzinga.com Why HyreCar Is Trading Higher By 60%, Here Are 63 Stocks Moving In Tuesday's Mid-Day Session Gainers HyreCar Inc. (NASDAQ: HYRE) jumped 60% to $1.2680 after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist…
- benzinga.com This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday Gainers
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's session, 340 companies made new 52-week lows.